Skip to main content
. 2018 Jan 8;8:119. doi: 10.1038/s41598-017-18375-x

Figure 4.

Figure 4

L-WNT3A treated autografts exhibit enhanced survival and osteogenesis. (A) Experimental design, where bone grafts were harvested, separated into mineralized matrix and marrow components then treated with either L-PBS or L-WNT3A. (B) qRT-PCR analyses of both components, showing fold-change in expression of Axin2, Runx2, and Osterix 24 h after treatment with L-PBS (white bars) or L-WNT3A (grey bars). TUNEL staining on representative tissue sections derived from aliquots of the mineralized matrix component of a bone graft treated with either (C) L-PBS or (D) L-WNT3A for 1 h then transplanted to the SRC for 10 days. (E) Quantification of TUNEL+ve cells/total number of viable, DAPI+ve cells on representative tissue sections. ALP staining on representative tissue sections derived from aliquots of the mineralized matrix component of a bone graft treated with either (F) L-PBS or (G) L-WNT3A; (H) quantification of ALP+ve pixels/total pixels. Aniline blue staining on representative tissue sections derived from aliquots of the mineralized matrix component of a bone graft treated with either (I) L-PBS or (J) L-WNT3A; (K) quantification of new bone volume. Scale bars = 50 µm. Asterisk indicates p-value < 0.05., double asterisks indicate p-value < 0.01.